Case Series: Use of Ziprasidone for Maladaptive Symptoms in Youths with Autism

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 41, Issue 8, 2002, Pages 921-927

  McDougle, Christopher J ^a   Kem, Deborah L ^a   Posey, David J ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Autism; Psychopharmacology; Ziprasidone

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; HALOPERIDOL; OLANZAPINE; PIMOZIDE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; TIOTIXENE; ZIPRASIDONE; PIPERAZINE DERIVATIVE; SEROTONIN ANTAGONIST; THIAZOLE DERIVATIVE;

ADOLESCENT; ADULT; AGGRESSION; AGITATION; ARTICLE; AUTISM; BODY WEIGHT DISORDER; CARDIOVASCULAR DISEASE; CHILD; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; DEVELOPMENTAL DISORDER; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; IRRITABILITY; MALADJUSTMENT; MALE; OPEN STUDY; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; RATING SCALE; SEDATION; SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECT; PSYCHOLOGICAL ASPECT; RESTLESSNESS;

ADOLESCENT; ADULT; AGGRESSION; AUTISTIC DISORDER; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IRRITABLE MOOD; MALE; PIPERAZINES; PSYCHOMOTOR AGITATION; SEROTONIN ANTAGONISTS; THIAZOLES;

EID: 0036674389     PISSN: 08908567     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004583-200208000-00010     Document Type: Article

References (36)

1. American Psychiatric Association (1994), Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV). Washington, DC: American Psychiatric Association
2. Arnold LE, Aman MG, Martin A et al. (2000), Assessment in multisite randomized clinical trials of patients with autistic disorder: the autism RUPP network. J Autism Dev Disord 30:99-111
3. Baldessarini R, Frankenburg FR (1991), Clozapine: a novel antipsychotic agent. N Engl J Med 324:746-754
4. Baxter LR, Phelps ME, Mazziotta JC, Guze BH, Schwartz JM Selin CE (1987), Local cerebral glucose metabolic rates in obsessive-compulsive disorder: a comparison with rates in unipolar depression and in normal controls. Arch Gen Psychiatry 44:211-218
5. Bymaster FP, Calligaro DO, Falcone JF et al. (1996), Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14:87-96
6. Campbell M, Anderson L, Meier M et al. (1978), A comparison of haloperidol and behavior therapy and their interaction in autistic children. J Am Acad Child Psychiatry 17:640-655
7. Chen NC, Bedair HS, McKay B, Bowers MB Jr, Mazure C (2001), Clozapine in the treatment of aggression in an adolescent with autistic disorder. J Clin Psychiatry 62:479-480
8. Czekalla J, Kollack-Walker S, Beasley CM Jr (2001), Cardiac safety parameters of olanzapine: comparison with other atypical and typical antipsychotics. J Clin Psychiatry 62(suppl 2):35-40
9. Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M (1999), Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Neuropsychopharmacology 20:491-505
10. Fisman S, Steele M (1996), Use of risperidone in pervasive developmental disorders: a case series. J Child Adolesc Psychopharmacol 6:177-190
11. Giller E, Mandel FS, Keck P (2001), Ziprasidone in the acute treatment of mania: a double-blind, placebo-controlled, randomized trial. Schizophr Res 49(suppl 1-2):229
12. Guy W (1976), ECDEUA Assessment Manual for Psychopharmacology (NIMH Publication 76-338). Washington, DC: DHEW, NIMH
13. Hellings JA, Zarcone JR, Crandall K, Wallace D, Schroeder SR (2001), Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism. J Child Adolesc Psychopharmacol 11:229-238
14. Heuring RE, Peroutka SJ (1987), Characterization of a novel 3H-5-hydroxytryptamine binding site subtype in bovine brain membranes. J Neurosci 7:894-903
15. Hollander E, Novotny S, Allen A, Aronowitz B, Cartwright C, DeCaria C (2000), The relationship between repetitive behaviors and growth hormone response to sumatriptan challenge in adult autistic disorder. Neuropsychopharmacology 22:163-167
16. Kay SR, Opler LA, Lindenmayer JP (1987), Reliability and validity of the positive and negative symptom scale for schizophrenia. Psychiatry Res 23:99-110
17. Keck P Jr, Buffenstein A, Ferguson J et al. (1998), Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology 140:173-184
18. Leysen JE, Gommeren W, Eens A, de Chaffoy de Courcelles D, Stoof JC, Janssen PA (1988), Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 247:661-670
19. Lord C, Rutter M, Le Couteur AM (1994), Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord 27:659-685
20. Malone RP, Cater J, Sheikh RM, Choudhury MS, Delaney MA (2001), Olanzapine versus haloperidol in children with autistic disorder: an open pilot study. J Am Acad Child Adolesc Psychiatry 40:887-894
21. Martin A, Koenig K, Scahill L, Bregman J (1999), Open-label quetiapine in the treatment of children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol 9:99-107
22. McDougle CJ, Holmes JP, Bronson MR et al. (1997), Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study. J Am Acad Child Adolesc Psychiatry 36:685-693
23. McDougle CJ, Holmes JP, Carlson DC, Pelton GH, Cohen DJ, Price LH (1998), A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch Gen Psychiatry 55:633-641
24. McDougle CJ, Scahill L, McCracken JT et al. (2000), Background and rationale for an initial controlled study of risperidone. Child Adolesc Psychiatr Clin North Am 9:201-224
25. Meltzer HY (1991), The mechanism of action of novel antipsychotic drugs. Schizophr Bull 17:263-287
26. Posey DJ, McDougle CJ (2000), The pharmacotherapy of target symptoms associated with autistic disorder and other pervasive developmental disorders. Harv Rev Psychiatry 8:45-63
27. Posey DJ, McDougle CJ (in press), Atypical antipsychotics in autism and other pervasive developmental disorders. In: Diagnosis and Treatment of Autism, Hollander E, Delaney K, eds. New York: Marcel Dekker
28. Potenza MN, Holmes JP, Kanes SJ, McDougle CJ (1999), Olanzapine treatment of children, adolescents and adults with pervasive developmental disorders: an open-label pilot study. J Clin Psychopharmacol 19:37-44
29. Potenza MN, McDougle CJ (1998), Potential of atypical antipsychotics in the treatment of nonpsychotic disorders. CNS Drugs 9:213-232
30. Psychopharmacological Drugs Advisory Committee (2000), FDA Background Document on Zeldox (PDAC 0700.M01). Rockville, MD: Food and Drug Administration
31. Sallee FR, Kurlan R, Goetz CG et al. (2000), Ziprasidone treatment of children and adolescents with Tourette's syndrome: a pilot study. J Am Acad Child Adolesc Psychiatry 39:292-299
32. Scahill L, McCracken J, McDougle CJ et al. (2001), Methodological issues in designing a multisite trial of risperidone in children and adolescents with autism. J Child Adolesc Psychopharmacol 11:377-388
33. Stigler KA, Potenza MN, McDougle CJ (2001), Tolerability profile of atypical antipsychotics in children and adolescents. Pediatr Drugs 3:927-942
34. Tandon R, Harrigan E, Zorn SH (1997), Ziptasidone: a novel antipsychotic with unique pharmacology and therapeutic potential. J Serotonin Res 4:159-177
35. Weiden PJ (2001), Ziprasidone: a new atypical antipsychotic. J Psychiatr Pract 7:145-153
36. Zuddas A, Ledda MG, Fratta A, Muglia P, Cianchetti C (1996), Clinical effects of clozapine on autistic disorder. Am J Psychiatry 153:738